Integrated Filing — IndAS



General information about company

Scrip Code 543960
NSE Symbol CONCORDBIO
MSEI Symbol NA
ISIN INE338H01029
Name of company CONCORD BIOTECH LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 29-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 23-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 29-05-2026   15:00:00
End date and time of board meeting 29-05-2026   16:24:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 08-08-2025
Indicate Company website link for updated RPT policy of the Company https://concordbiotech.com/wp-content/uploads/2025/09/12.-Concord-Biotech-Limited-Policy-on-Related-Party-Transactions-1.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There are no defaults on loans and debt securities



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 32,589.20 1,05,507.10
Other income 1,554.17 5,273.06
Total income 34,143.37 1,10,780.16
2 Expenses
(a) Cost of materials consumed 7,054.09 25,434.78
(b) Purchases of stock-in-trade 1,567.01 6,222.86
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (53.57) (7,061.49)
(d) Employee benefit expense 4,501.87 17,018.60
(e) Finance costs 5.84 23.40
(f) Depreciation, depletion and amortisation expense 1,948.67 7,432.51
(f) Other Expenses
1 Power and fuel 2,975.97 11,619.93
2 Others 4,305.73 14,618.85
Total other expenses 7,281.70 26,238.78
Total expenses 22,305.61 75,309.44
3 Total profit before exceptional items and tax 11,837.76 35,470.72
4 Exceptional items 0.00 (327.54)
5 Total profit before tax 11,837.76 35,143.18
6 Tax expense
7 Current tax 2,864.81 8,629.09
8 Deferred tax (29.26) 187.42
9 Total tax expenses 2,835.55 8,816.51
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 9,002.21 26,326.67
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 9,002.21 26,326.67
17 Other comprehensive income net of taxes 1,361.34 5,577.81
18 Total Comprehensive Income for the period 10,363.55 31,904.48
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,046.16 1,046.16
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 2,00,929.01
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 8.6 25.17
Diluted earnings (loss) per share from continuing operations 8.6 25.17
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 8.6 25.17
Diluted earnings (loss) per share from continuing and discontinued operations 8.6 25.17
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes to the statement of standalone financial results for the quarter and year ended March 31 2026 1 The above standalone financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on May 29 2026. The Statutory Auditors of the company have carried out audit of the said results. 2 The figures for the quarter ended March 31 2026 and March 31 2025 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended December 31 2025 and December 31 2024 respectively which were subjected to limited review. 3 On 21 November 2025 the Government of India notified four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour and Employment has issued draft Central Rules and FAQs to facilitate assessment of the financial impact arising from these changes. Based on management’s assessment including actuarial valuation, considering the best information available and ICAI guidance, the Company has recognised an incremental liability of Rs 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under the New Labour Codes. Considering the event as regulatory-driven and non-recurring in nature, the impact of the same has been disclosed under exceptional items in the standalone results ffor the year ended 31 March 2026. The Company continues to monitor the notification of final Central/State rules and related clarifications and will evaluate and account for any additional impact in the period in which such rules are notified or clarifications issued. 4 The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard Ind AS 108 Operating Segment. 5 The above standalone financial results has been prepared in accordance with Indian Accounting Standards Ind AS notified under Section 133 of the Companies Act 2013 read together with Companies Indian Accounting Standards Rules 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India SEBI. 6 Celliimune Biotech Private Limited that is incorporated on 15 January 2025 has been acquired by Concord Biotech Limited as on 2 April 2026. As at 31 March 2026 the company has invested Rs. 1.2 Lakhs for acquisition of shares out of total consideration of Rs 66 Lakhs for this acquisition. Celliimune Biotech Private Limited became a wholly owned subsidiary on 2 April 2026. 7 The board of directors have recommended final dividend of Rs. 7.55 per fully paid up equity share of Rs. 1 each for financial year ended March 31 2026 on outstanding paid up share capital of the company as on date in its board meeting held on May 29 2026 subject to approval of shareholders at ensuing annual general meeting of the Company.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 78,563.34
Capital work-in-progress 7,815.92
Investment property
Goodwill 0.00
Other intangible assets 78.09
Intangible assets under development 116.51
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 8,562.52
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other Financial Assets 2,120.45
Total of other non-current financial assets 2,120.45
Total non-current financial assets 10,682.97
Deferred tax assets (net) 283.81
Other non-current assets
1 Prepaid expenses 492.11
2 Capital advances 961.17
3 Balances with government authorities 138.25
Total of other non-current assets 1,591.53
Total non-current assets 99,132.17
2 Current assets
Inventories 32,568.80
Current financial asset
Current investments 40,206.37
Trade receivables, current 46,060.15
Cash and cash equivalents 788.89
Bank balance other than cash and cash equivalents 139.30
Loans, current 0.00
Other current financial assets
Total of other current financial assets 2,529.66
Total current financial assets 89,724.37
Current tax assets (net) 0.00
Other current assets
1 Other Current Assets 2,228.44
Total of other current assets 2,228.44
Total current assets 1,24,521.61
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 2,23,653.78
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,046.16
Other equity 2,00,929.01
Total equity attributable to owners of parent 2,01,975.17
Non controlling interest
Total equity 2,01,975.17
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liabilities 45.55
Total of other non-current financial liabilities 45.55
Total non-current financial liabilities 45.55
Provisions, non-current 371.97
Deferred tax liabilities (net) 4,536.62
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 4,954.14
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,474.95
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 8,643.23
Total Trade payable 10,118.18
Other current financial liabilities
1 Other current financial liabilities 4,232.53
2 Lease Liabilities 17.43
Total of other current financial liabilities 4,249.96
Total current financial liabilities 14,368.14
Other current liabilities 1,231.92
1 Other current liabilities 1,231.92
Total of other current liabilities 1,231.92
Provisions, current 1,123.43
Current tax liabilities (Net) 0.98
Deferred government grants, Current 0.00
Total current liabilities 16,724.47
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 21,678.61
Total equity and liabilites 2,23,653.78
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement gain/ (loss) on defined benefit plans (68.75) (162.24)
2 Income tax relating to re-measurement gain/ (loss) on defined benefit plans 17.30 40.83
3 Fair value changes on equity investments through OCI 1,685.42 6,687.09
4 Income tax relating to fair value changes on equity investments through OCI (272.63) (987.87)
Total Amount of items that will not be reclassified to profit and loss 1,361.34 5,577.81
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 1,361.34 5,577.81



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 35,143.18
Adjustments for reconcile profit (loss)
Adjustments for finance costs 23.40
Adjustments for decrease (increase) in inventories (8,602.08)
Adjustments for decrease (increase) in trade receivables, current 7,004.85
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (808.86)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (55.23)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (919.11)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 100.06
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 7,432.51
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 497.17
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current (128.83)
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (1,094.81)
Adjustments for dividend income 0.00
Adjustments for interest income 281.85
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (959.64)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (1,154.43)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (71.74)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 981.41
Net cash flows from (used in) operations 36,124.59
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 9,746.94
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 26,377.65
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 3.49
Other cash receipts from sales of equity or debt instruments of other entities 88,240.88
Other cash payments to acquire equity or debt instruments of other entities 94,680.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 9,503.96
Proceeds from sales of investment property 10.03
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 1,544.72
Purchase of other long-term assets 111.44
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 275.33
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (14,227.93)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 38.11
Payments of lease liabilities 219.24
Dividends paid 11,193.93
Interest paid 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (11,451.28)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 698.44
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 698.44
Cash and cash equivalents cash flow statement at beginning of period 90.45
Cash and cash equivalents cash flow statement at end of period 788.89





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 B S R & Co. LLP Yes 31-07-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Concord Biotech Limited Concord Biotech Japan K.K Joint Venture Sale of goods or services 1,320.71 As per Companies Act 2013 and approved by Board 1,320.71 800.76 363.87
2 Concord Biotech Limited Sudhir Vaid Key Management Personnel Any other transaction Lease Rent Paid 74.48 As per Companies Act 2013 and approved by Board 74.48 0.00 0.00
3 Concord Biotech Limited Manju Vaid Relatives of Key Management Personnel Any other transaction Lease Rent Paid 23.89 As per Companies Act 2013 and approved by Board 23.89 0.00 0.00
4 Concord Biotech Limited Col S. K Vaid Relatives of Key Management Personnel Any other transaction Professional Fees 27.72 As per Companies Act 2013 and approved by Board 27.72 4.99 4.99
5 Concord Biotech Limited Ravi Kapoor & Associates Enterprises controlled by / under significantly influenced by Directors and/or their relatives: Any other transaction Professional Fees 15.67 As per Companies Act 2013 and approved by Board 15.67 2.06 2.21
6 Concord Biotech Limited Sudhir Vaid Key Management Personnel Remuneration 393.23 As per Companies Act 2013 and approved by Board 393.23 28.75 108.23
7 Concord Biotech Limited Ankur Vaid Key Management Personnel Remuneration 210.49 As per Companies Act 2013 and approved by Board 210.49 16.69 47.02
8 Concord Biotech Limited Megha Vaid Relatives of Key Management Personnel Remuneration 55.41 As per Companies Act 2013 and approved by Board 55.41 4.82 4.95
9 Concord Biotech Limited Sonal Kumra Relatives of Key Management Personnel Remuneration 61.21 As per Companies Act 2013 and approved by Board 61.21 5.17 5.03
10 Concord Biotech Limited Lalit Sethi Key Management Personnel Remuneration 13.26 As per Companies Act 2013 and approved by Board 13.26 4.11 0.00
11 Concord Biotech Limited Raviraj Karia Key Management Personnel Remuneration 22.66 As per Companies Act 2013 and approved by Board 22.66 0.00 3.49
12 Concord Biotech Limited Hina Ronak Patel Key Management Personnel Remuneration 4.88 As per Companies Act 2013 and approved by Board 4.88 0.76 0.00
13 Concord Biotech Limited Paritosh Trivedi Key Management Personnel Remuneration 1.76 As per Companies Act 2013 and approved by Board 1.76 0.00 0.82
14 Concord Biotech Limited Ravi Kapoor Key Management Personnel Any other transaction Sitting Fees 1.95 As per Companies Act 2013 and approved by Board 1.95 0.00 0.00
15 Concord Biotech Limited Amitabh Thakore Key Management Personnel Any other transaction Sitting Fees 2.70 As per Companies Act 2013 and approved by Board 2.70 0.00 0.00
16 Concord Biotech Limited Rajiv Agrawal Key Management Personnel Any other transaction Sitting Fees 1.80 As per Companies Act 2013 and approved by Board 1.80 0.00 0.00
17 Concord Biotech Limited Bharti Khanna Key Management Personnel Any other transaction Sitting Fees 2.10 As per Companies Act 2013 and approved by Board 2.10 0.00 0.00
18 Concord Biotech Limited Mandayam Chakravarthy Sriraman Key Management Personnel Any other transaction Sitting Fees 2.25 As per Companies Act 2013 and approved by Board 2.25 0.00 0.00
19 Concord Biotech Limited Arvind Agarwal Key Management Personnel Any other transaction Sitting Fees 2.25 As per Companies Act 2013 and approved by Board 2.25 0.00 0.00
20 Concord Biotech Limited Jayaram Easwaran Key Management Personnel Any other transaction Sitting Fees 2.40 As per Companies Act 2013 and approved by Board 2.40 0.00 0.00
21 Concord Biotech Limited Celliimune Biotech Private Limited Enterprises controlled by or under significantly influenced by Directors and or their relatives Investment 1.20 As per Companies Act 2013 and approved by Board 1.20 0.00 1.20
22 Concord Biotech Limited Ravi Kapoor Key Management Personnel Any other transaction Purchase of Equity Shares from KMP 1.20 As per Companies Act 2013 and approved by Board 1.20 0.00 0.00
23 Concord Biotech Limited Stellon Biotech In Subsidiary Company Interest received 28.56 As per Companies Act 2013 and approved by Board 28.56 7.77 0.00
24 Concord Biotech Limited Concord Lifegen Ltd Subsidiary Company Any other transaction Rent Income from Subsidiary Company 3.20 As per Companies Act 2013 and approved by Board 3.20 0.00 0.00
25 Concord Biotech Limited Stellon Biotech In Subsidiary Company Loan 986.39 As per Companies Act 2013 and approved by Board 986.39 432.50 1,455.22
26 Concord Biotech Limited Concord Lifegen Ltd Subsidiary Company Loan 20.29 As per Companies Act 2013 and approved by Board 20.20 5.00 25.20
27 Concord Biotech Limited Concord Lifegen Ltd Subsidiary Company Sale of goods or services 59.74 As per Companies Act 2013 and approved by Board 59.74 0.00 62.71
28 Concord Biotech Limited Concord Lifegen Ltd Subsidiary Company Investment 0.00 As per Companies Act 2013 and approved by Board 0.00 1.00 1.00
29 Concord Biotech Limited Stellon Biotech In Subsidiary Company Investment 0.00 As per Companies Act 2013 and approved by Board 0.00 1.28 1.28
30 Concord Biotech Limited Concord Lifegen Ltd Subsidiary Company Interest received 0.59 As per Companies Act 2013 and approved by Board 0.59 0.00 0.59
Total value of transaction during the reporting period 3,341.90